1.International Diabetes Federation (IDF). Diabetes atlas - 8th edition. Available at: http://www.diabetesatlas.org/.
2.American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013 Apr;36(4):1033–46.
3.Jonsson B. Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002;45(7):S5–12.
4.American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018 May;41(5):917–28.
5.Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12;321(7258):405–12.
6.The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993 Sep 30;329(14):977–86.
7.Bulgarian Society of Endocrinology. Good clinical practice guidelines on diabetes mellitus. 2016.
8.Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669–701.
9.Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care. 2011 Feb;34(2):510–7.
10.International Diabetes Federation (IDF) Clinical Guidelines Task Force. Global guideline for type 2 diabetes, 2012. Available at https://www.idf.org/e-library/guidelines/79-global-guideline-for-type–2-diabetes
11.American Diabetes Association. Standards of medical care in diabetes–2018. Diabetes Care. 2018 Jan;41(Suppl 1):S1-S153.
12.Blak BT, Smith HT, Hards M, Curtis BH, Ivanyi T. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. Diabet Med. 2012 Jul;29(7):e13–20.
13.de Pablos-Velasco P, Parhofer KG, Bradley C, Eschwege E, Gonder-Frederick L, Maheux P, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf). 2014 Jan;80(1):47–56.
14.Govan L, Wu O, Briggs A, Colhoun HM, Fischbacher CM, Leese GP, et al. Achieved levels of HbA1c and likelihood of hospital admission in people with type 1 diabetes in the Scottish population: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetes Care. 2011 Sep;34(9):1992–7.
15.NHS Health & Social Care Information Centre. National Diabetes Audit 2011–2012; Report 1: Care Processes and Treatment Targets, available at http://content.digital.nhs.uk/catalogue/PUB12421/nati-diab-audi–11–12-care-proc-rep.pdf.
16.Cokolic M, Lalic NM, Micic D, Mirosevic G, Klobucar Majanovic S, Lefterov IN, et al. Patterns of diabetes care in Slovenia, Croatia, Serbia, Bulgaria and Romania. Wiener klinische Wochenschrift. 2017 2017/03/01;129(5):192–200.
17.Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract. 2007;57(539):455–60.
18.Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK. Diabet Med. 2007;24(12):1412–8.
19.Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673–9.
20.Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012 Oct;14(10):944–50.
21.Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014 Sep;53(9):787–800.
22.Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012 Sep;14(9):859–64.
23.Heise T, Norskov M, Nosek L, Kaplan K, Famulla S, Haahr HL. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab. 2017 Jul;19(7):1032–9.
24.Heise T, Kaplan K, Haahr HL. Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies. J Diabetes Sci Technol. 2018 Mar;12(2):356–63.
25.European Medicines Agency. Tresiba® (insulin degludec) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/documents/product-information/tresiba-epar-product-information_en.pdf.
26.Wangnoo SK, Chowdhury S, Rao PV. Treating to target in type 2 diabetes: the BEGIN trial programme. J Assoc Physicians India. 2014 Jan;62(1 Suppl):21–6.
27.Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes therapy: research, treatment and education of diabetes and related disorders. 2014 Dec;5(2):435–46.
28.Ratner R, Gough SC, Mathieu C, Prato SD, Bode B, Mersebach H, et al. Hypoglycaemia Risk With Insulin Degludec Compared With Insulin Glargine in Type 2 and Type 1 Diabetes: A Pre-planned Meta-Analysis of Phase 3 Trials. Diabetes Obes Metab. 2013 Nov 6;15(2):175–84.
29.Siegmund T, Tentolouris N, Knudsen ST, Lapolla A, Prager R, Phan TM, et al. A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes. Diabetes Obes Metab. 2018 Mar;20(3):689–97.
30.Evans M, McEwan P, Foos V. Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice-a case-based evaluation. J Med Econ. 2015 Feb;18(2):96–105.
31.Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006 Sep;21(5):402–8.
32.Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001. Available from: http://apps.who.int/iris/bitstream/10665/42435/1/924154550X.pdf.
33.Evans M, Chubb B, Gundgaard J. Cost-effectiveness of insulin degludec versus insulin glargine in adults with type 1 and type 2 diabetes mellitus. Diabetes therapy: research, treatment and education of diabetes and related disorders. 2017 Apr;8(2):275–91.
34.Lalic N, Russel-Szymczyk M, Culic M, Tikkanen CK, Chubb B. Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia. Diabetes therapy: research, treatment and education of diabetes and related disorders. 2018 Jun;9(3):1201–16.
35.Doneva M, Valov V, Borisova A-M, Tankova T, Savova A, Manova M, et al. Comparative Analysis of the Cost of Insulin Treated Patients in Bulgaria. Biotechnology & Biotechnological Equipment. 2013 2013/01/01;27(2):3748–52.
36.UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007 Jun;50(6):1140–7.
37.Brod M, Rana A, Barnett AH. Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians. Curr Med Res Opin. 2012 Dec;28(12):1947–58.
38.Heller SR, Frier BM, Herslov ML, Gundgaard J, Gough SC. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources. Diabet Med. 2016 Jul 16;33:471–7.
39.Evans M, Khunti K, Mamdani M, Galbo-Jorgensen CB, Gundgaard J, Bogelund M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013 Jun 3;11(1):90.
40.Boye KS, Matza LS, Walter KN, Van Brunt K, Palsgrove AC, Tynan A. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ. 2011 Jun;12(3):219–30.
41.Ericsson A, Pollock RF, Hunt B, Valentine WJ. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. J Med Econ. 2013 Dec;16(12):1442–52.
42.Pollock RF, Tikkanen CK. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark. J Med Econ. 2017 Mar;20(3):213–20.
43.Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective. Diabetes Obes Metab. 2014 Apr;16(4):366–75.
44.Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. J Med Econ. 2015 Jan;18(1):56–68.
45.Frier BM. The economic costs of hypoglycaemia. Br J Diabetes Vasc Dis. 2011;11(Suppl 1):S10-S2.
46.Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2015 Feb;38(2):316–22.
47.Graveling AJ, Frier BM. Impaired awareness of hypoglycaemia: a review. Diabetes Metab. 2010 Oct;36 Suppl 3:S64–74.
48.Khunti K, Alsifri S, Aronson R, Cigrovski Berkovic M, Enters-Weijnen C, Forsen T, et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016 Sep;18(9):907–15.
49.Landstedt-Hallin L, Gundgaard J, Ericsson A, Ellfors-Zetterlund S. Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data. Curr Med Res Opin. 2017 Apr;33(4):647–55.
50.Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012 May;29(5):682–9.
51.Khunti K, Alsifri S, Aronson R, Cigrovski Berkovic M, Enters-Weijnen C, Forsen T, et al. Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes. Diabetes Res Clin Pract. 2017 Aug;130:121–9.
52.Diabetes UK. Facts and stats 2016. Available at: https://www.diabetes.org.uk/Documents/Position%20statements/DiabetesUK_Facts_Stats_Oct16.pdf.
53.Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA. 2017 Jul 04;318(1):33–44.
54.Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA. 2017 Jul 04;318(1):45–56.
55.Evans M, Mehta R, Gundgaard J, Chubb B. Cost-effectiveness of insulin degludec vs. insulin glargine U100 in type 1 and type 2 diabetes mellitus in a UK setting. Diabetes therapy: research, treatment and education of diabetes and related disorders. 2018 Oct;9(5):1919–30.
56.Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo Francisco AM, Rothman J. Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use). Adv Ther. 2013 Jun;30(6):607–22.
57.Evans M, Jensen HH, Bogelund M, Gundgaard J, Chubb B, Khunti K. Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey. J Med Econ. 2013 Nov;16(11):1357–65.
58.Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017 Aug 24;377(8):723–32.
59.Ostenson CG, Geelhoed-Duijvestijn P, Lahtela J, Weitgasser R, Markert Jensen M, Pedersen-Bjergaard U. Self-reported non-severe hypoglycaemic events in Europe. Diabet Med. 2014 Jan;31(1):92–101.